System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Lucienne Costa-Frossard is an expert in Neurology at Hospital Universitario Ramón y Cajal (Spain). As of October 2026, ScienceLeadR ranks Lucienne Costa-Frossard in the top 1% of experts worldwide for Primary Progressive Multiple Sclerosis, Multiple Sclerosis and Autoimmune Diseases. Lucienne Costa-Frossard has authored 148 publications, the most recent in 2026, and is an investigator in 20 clinical trials, 8 of them ongoing. SLR score: 853 (community average: 125). How the SLR is computed.

LeadR Profile

Lucienne Costa-Frossard Hospital Universitario Ramón y Cajal Spain
853 ScienceLeadR Reputation 853

Unlock

Register Login
Network Map

Neurology

Subspecialties: Immunology - Biochemistry - Hematology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2009 - 2026
Source: PubMed

Hospital Universitario Ramón y Cajal

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 148

Citations

Citations: 1 535 1st author: 4 Last author: 5 Unique author: 1

Main journals

Front Immunol 15
Rev Neurol 15
Neurology 14
Mult Scler Relat Disord 11
Front Neurol 6

Best Journals

Lancet Neurol 2
N Engl J Med 2
Lancet 1

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
Measurable residual disease-guided, fixed-duration, potentially definitive therapy for standard risk newly diagnosed multiple myeloma.
PMID 42839068 — leukemia, multiple myeloma, therapeutics		Leukemia20260
Kappa index: real-world study for assessing cut-off values that provide the best accuracy for multiple sclerosis diagnosis in patients with CIS.
PMID 42712420 — sclerosis, multiple sclerosis, neuritis, immune system diseases, optic neuritis, diagnosis, sensitivity and specificity		Front Immunol20260
[XVIII Post-ECTRIMS Meeting: Review of the New Developments Presented at the 2025 ECTRIMS Congress (Part I)].
PMID 42689738 — cells, multiple sclerosis, spinal cord, biomarkers, neuromyelitis optica, diagnosis, therapeutics, neurology, spine		Rev Neurol20260
[XVIII Post-ECTRIMS Meeting: Review of the New Developments Presented at the 2025 ECTRIMS Congress (Part II)].
PMID 42689737 — multiple sclerosis, biomarkers, aged, therapeutics, neurology		Rev Neurol20260
Discontinuation of disease-modifying therapies in patients with multiple sclerosis: A retrospective case-control study.
PMID 42385519 — sclerosis, multiple sclerosis, case-control studies, therapeutics		Mult Scler Relat Disord20261

Clinical Studies 20

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 2

By phase:

Phase 3 16
Phase 2 3
N/A 1

By status:

Active not recruiting 9
Completed 5
Recruiting 4
Terminated 2

By type:

Interventional 19
Observational 1

By Monocentric/Multicentric:

monocentric 0
multicentric2to4 0
multicentric5to9 1
multicentricup10 19

Main Topics

Ongoing Clinical Trials

8 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A Study to Evaluate Safety and Efficacy of Ocrelizumab in Comparison with Fingolimod in Children and Adolescents with Relapsing Remitting Multiple Sclerosis
2023-506516-40-00 — sclerosis, multiple sclerosis, safety, adolescent, multiple sclerosis, relapsing-remitting, child		Phase 3Active not recruiting2022
A study to investigate long term safety and tolerability of tolebrutinib in participants with multiple sclerosis
2023-503631-18-01 — sclerosis, multiple sclerosis, safety, nervous system, nervous system diseases, primary progressive multiple sclerosis, secondary progressive multiple sclerosis		Phase 3Active not recruiting2024
Study of an On Body Injection System for Home Use of Ocrelizumab in People with Multiple Sclerosis
2025-523726-40-00 — injections, sclerosis, multiple sclerosis, safety, multiple chronic conditions		Phase 3Recruiting2026
A clinical trial to find out how well LOU064 (remibrutinib) works and how safe it is for people with secondary progressive multiple sclerosis
2025-521546-23-00 — sclerosis, multiple sclerosis, safety, secondary progressive multiple sclerosis		Phase 3Recruiting2026
A Study to Assess Bioequivalence of Two Subcutaneous Formulations of Ocrelizumab in Participants with Multiple Sclerosis
2024-517980-22-00 — sclerosis, multiple sclerosis, therapeutic equivalency		Phase 2Active not recruiting2025

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS